O	0	8	Efficacy
O	9	11	of
B-intervention	12	22	everolimus
I-intervention	23	27	with
I-intervention	28	38	exemestane
O	39	45	versus
B-control	46	56	exemestane
I-control	57	62	alone
O	63	65	in
B-ethinicity	66	71	Asian
B-eligibility	72	80	patients
I-eligibility	81	85	with
I-eligibility	86	90	HER2
I-eligibility	90	91	-
I-eligibility	91	99	negative
I-eligibility	99	100	,
I-eligibility	101	108	hormone
I-eligibility	108	109	-
I-eligibility	109	117	receptor
I-eligibility	117	118	-
I-eligibility	118	126	positive
I-eligibility	127	133	breast
I-eligibility	134	140	cancer
O	141	143	in
O	144	150	BOLERO
O	150	151	-
O	151	152	2
O	152	153	.

O	154	157	The
O	158	166	addition
O	167	169	of
O	170	174	mTOR
O	175	184	inhibitor
O	185	195	everolimus
O	196	197	(
O	197	200	EVE
O	200	201	)
O	202	204	to
O	205	215	exemestane
O	216	217	(
O	217	220	EXE
O	220	221	)
O	222	225	was
O	226	235	evaluated
O	236	238	in
O	239	241	an
O	242	255	international
O	255	256	,
O	257	262	phase
O	263	264	3
O	265	270	study
O	271	272	(
O	272	278	BOLERO
O	278	279	-
O	279	280	2
O	280	281	)
O	282	284	in
O	285	293	patients
O	294	298	with
O	299	306	hormone
O	306	307	-
O	307	315	receptor
O	315	316	-
O	316	324	positive
O	325	326	(
O	326	328	HR
O	328	329	(
O	329	330	+
O	330	331	)
O	331	332	)
O	333	339	breast
O	340	346	cancer
O	347	357	refractory
O	358	360	to
O	361	370	letrozole
O	371	373	or
O	374	385	anastrozole
O	385	386	.

O	387	390	The
O	391	397	safety
O	398	401	and
O	402	410	efficacy
O	411	413	of
O	414	424	anticancer
O	425	435	treatments
O	436	439	may
O	440	442	be
O	443	453	influenced
O	454	456	by
O	457	466	ethnicity
O	467	468	(
O	468	474	Sekine
O	475	477	et
O	478	480	al
O	480	481	.
O	482	484	in
O	485	487	Br
O	488	489	J
O	490	496	Cancer
O	497	499	99
O	499	500	:
O	500	504	1757
O	504	505	-
O	505	507	62
O	507	508	,
O	509	513	2008
O	513	514	)
O	514	515	.

O	516	522	Safety
O	523	526	and
O	527	535	efficacy
O	536	543	results
O	544	548	from
O	549	554	Asian
O	555	561	versus
B-ethinicity	562	565	non
I-ethinicity	565	566	-
I-ethinicity	566	571	Asian
O	572	580	patients
O	581	583	in
O	584	590	BOLERO
O	590	591	-
O	591	592	2
O	593	596	are
O	597	605	reported
O	605	606	.

O	607	615	Patients
O	616	620	were
O	621	631	randomized
O	632	633	(
O	633	634	2
O	634	635	:
O	635	636	1
O	636	637	)
O	638	640	to
O	641	643	10
O	644	646	mg
O	646	647	/
O	647	650	day
O	651	654	EVE
O	655	656	+
O	657	660	EXE
O	661	663	or
B-control	664	671	placebo
I-control	672	673	(
I-control	673	676	PBO
I-control	676	677	)
I-control	678	679	+
I-control	680	683	EXE
O	683	684	.

O	685	692	Primary
O	693	701	endpoint
O	702	705	was
B-outcome-Measure	706	717	progression
I-outcome-Measure	717	718	-
I-outcome-Measure	718	722	free
I-outcome-Measure	723	731	survival
I-outcome-Measure	732	733	(
I-outcome-Measure	733	736	PFS
I-outcome-Measure	736	737	)
O	737	738	.

O	739	748	Secondary
O	749	758	endpoints
O	759	767	included
B-outcome-Measure	768	775	overall
I-outcome-Measure	776	784	survival
O	784	785	,
B-outcome-Measure	786	794	response
I-outcome-Measure	795	799	rate
O	799	800	,
B-outcome-Measure	801	809	clinical
I-outcome-Measure	810	817	benefit
I-outcome-Measure	818	822	rate
O	822	823	,
O	824	827	and
B-outcome-Measure	828	834	safety
O	834	835	.

O	836	838	Of
B-total-participants	839	842	143
O	843	848	Asian
O	849	857	patients
O	857	858	,
B-intervention-participants	859	861	98
O	862	870	received
O	871	874	EVE
O	875	876	+
O	877	880	EXE
O	881	884	and
B-control-participants	885	887	45
O	888	896	received
O	897	900	PBO
O	901	902	+
O	903	906	EXE
O	906	907	.

O	908	917	Treatment
O	918	922	with
O	923	926	EVE
O	927	928	+
O	929	932	EXE
O	933	946	significantly
O	947	955	improved
B-outcome	956	962	median
I-outcome	963	966	PFS
O	967	973	versus
O	974	977	PBO
O	978	979	+
O	980	983	EXE
O	984	989	among
O	990	995	Asian
O	996	1004	patients
O	1005	1007	by
O	1008	1010	38
O	1011	1012	%
O	1013	1014	(
O	1014	1016	HR
O	1017	1018	=
O	1019	1020	0
O	1020	1021	.
O	1021	1023	62
O	1023	1024	;
O	1025	1027	95
O	1028	1029	%
O	1030	1032	CI
O	1032	1033	,
O	1034	1035	0
O	1035	1036	.
O	1036	1038	41
O	1038	1039	-
O	1039	1040	0
O	1040	1041	.
O	1041	1043	94
O	1043	1044	)
O	1044	1045	.

B-outcome	1046	1052	Median
I-outcome	1053	1056	PFS
O	1057	1060	was
O	1061	1065	also
O	1066	1074	improved
O	1075	1080	among
O	1081	1084	non
O	1084	1085	-
O	1085	1090	Asian
O	1091	1099	patients
O	1100	1102	by
O	1103	1105	59
O	1106	1107	%
O	1108	1109	(
O	1109	1111	HR
O	1112	1113	=
O	1114	1115	0
O	1115	1116	.
O	1116	1118	41
O	1118	1119	;
O	1120	1122	95
O	1123	1124	%
O	1125	1127	CI
O	1127	1128	,
O	1129	1130	0
O	1130	1131	.
O	1131	1133	33
O	1133	1134	-
O	1134	1135	0
O	1135	1136	.
O	1136	1138	50
O	1138	1139	)
O	1139	1140	.

B-outcome	1141	1147	Median
I-outcome	1148	1151	PFS
O	1152	1160	duration
O	1161	1166	among
O	1167	1170	EVE
O	1170	1171	-
O	1171	1178	treated
O	1179	1184	Asian
O	1185	1193	patients
O	1194	1197	was
B-iv-cont-median	1198	1199	8
I-iv-cont-median	1199	1200	.
I-iv-cont-median	1200	1202	48
O	1203	1209	versus
B-cv-cont-median	1210	1211	4
I-cv-cont-median	1211	1212	.
I-cv-cont-median	1212	1214	14
I-cv-cont-median	1215	1221	months
O	1222	1225	for
O	1226	1229	PBO
O	1230	1231	+
O	1232	1235	EXE
O	1235	1236	,
O	1237	1240	and
B-iv-cont-median	1241	1242	7
I-iv-cont-median	1242	1243	.
I-iv-cont-median	1243	1245	33
O	1246	1252	versus
B-cv-cont-median	1253	1254	2
I-cv-cont-median	1254	1255	.
I-cv-cont-median	1255	1257	83
I-cv-cont-median	1258	1264	months
O	1264	1265	,
O	1266	1278	respectively
O	1278	1279	,
B-outcome	1280	1282	in
I-outcome	1283	1286	non
I-outcome	1286	1287	-
I-outcome	1287	1292	Asian
I-outcome	1293	1301	patients
O	1301	1302	.

O	1303	1306	The
O	1307	1311	most
O	1312	1318	common
B-outcome	1319	1324	grade
I-outcome	1325	1326	3
I-outcome	1326	1327	/
I-outcome	1327	1328	4
I-outcome	1329	1336	adverse
I-outcome	1337	1343	events
O	1344	1345	(
O	1345	1355	stomatitis
O	1355	1356	,
O	1357	1363	anemia
O	1363	1364	,
O	1365	1373	elevated
O	1374	1379	liver
O	1380	1387	enzymes
O	1387	1388	,
O	1389	1402	hyperglycemia
O	1402	1403	,
O	1404	1407	and
O	1408	1415	dyspnea
O	1415	1416	)
O	1417	1425	occurred
O	1426	1428	at
O	1429	1436	similar
O	1437	1448	frequencies
O	1449	1451	in
O	1452	1457	Asian
O	1458	1461	and
O	1462	1465	non
O	1465	1466	-
O	1466	1471	Asian
O	1472	1480	patients
O	1480	1481	.

B-outcome	1482	1487	Grade
I-outcome	1488	1489	1
I-outcome	1489	1490	/
I-outcome	1490	1491	2
I-outcome	1492	1504	interstitial
I-outcome	1505	1509	lung
I-outcome	1510	1517	disease
O	1518	1526	occurred
O	1527	1531	more
O	1532	1542	frequently
O	1543	1545	in
O	1546	1551	Asian
O	1552	1560	patients
O	1560	1561	.

B-outcome	1562	1569	Quality
I-outcome	1570	1572	of
I-outcome	1573	1577	life
O	1578	1581	was
O	1582	1589	similar
O	1590	1597	between
O	1598	1607	treatment
O	1608	1612	arms
O	1613	1615	in
O	1616	1621	Asian
O	1622	1630	patients
O	1630	1631	.

O	1632	1638	Adding
O	1639	1642	EVE
O	1643	1645	to
O	1646	1649	EXE
O	1650	1658	provided
O	1659	1670	substantial
O	1671	1679	clinical
O	1680	1687	benefit
O	1688	1690	in
O	1691	1695	both
O	1696	1701	Asian
O	1702	1705	and
O	1706	1709	non
O	1709	1710	-
O	1710	1715	Asian
O	1716	1724	patients
O	1725	1729	with
O	1730	1737	similar
O	1738	1744	safety
O	1745	1753	profiles
O	1753	1754	.

O	1755	1759	This
O	1760	1771	combination
O	1772	1782	represents
O	1783	1785	an
O	1786	1797	improvement
O	1798	1800	in
O	1801	1804	the
O	1805	1815	management
O	1816	1818	of
O	1819	1833	postmenopausal
O	1834	1839	women
O	1840	1844	with
O	1845	1847	HR
O	1847	1848	(
O	1848	1849	+
O	1849	1850	)
O	1850	1851	/
O	1851	1855	HER2
O	1855	1856	(
O	1856	1857	-
O	1857	1858	)
O	1859	1867	advanced
O	1868	1874	breast
O	1875	1881	cancer
O	1882	1893	progressing
O	1894	1896	on
O	1897	1909	nonsteroidal
O	1910	1919	aromatase
O	1920	1930	inhibitors
O	1930	1931	,
O	1932	1942	regardless
O	1943	1945	of
O	1946	1955	ethnicity
O	1955	1956	.
